Table 1. Patient characteristics for the study cohort and by treatment group.
| Entire Cohort | Radiation | Non-Radiation | |
|---|---|---|---|
|
| |||
| Chloroma Cases | 38 | 22 | 16 |
|
| |||
| Gender | Male 25 (66%) | Male 14 (63%) | Male 11 (69%) |
| Female 13 (34%) | Female 8 (36%) | Female 5 (31%) | |
|
| |||
| Ethnicity | White 28 (74%) | White 15 (68%) | White 13 (81%) |
| Black 2 (5%) | Black 2 (9%) | Black 0 (0%) | |
| Hispanic 5 (13%) | Hispanic 4 (18%) | Hispanic 1 (6%) | |
| Asian 3 (8%) | Asian 1 (5%) | Asian 2 (13%) | |
|
| |||
| Cancer Diagnosis | AML* 29 (76%) CML† 1 (3%) MDS†† 3 (8%) Isolated Chloroma 5 (13%) |
AML 19 (86%) MDS 2 (9%) Isolated Chloroma 1 (5%) |
AML 10 (63%) CML 1 (6%) MDS 1 (6%) Isolated Chloroma 4 (25%) |
|
| |||
| Median Age at Leukemia Diagnosis (years) | 44 (1-71) | 33 (1-70) | 49 (10-71) |
|
| |||
| Median Age at Chloroma Diagnosis (years) | 44 (1-71) | 34 (1-71) | 49 (10-71) |
|
| |||
| Patients with Chloroma at Presentation | 18 (47%) | 4 (18%) | 14 (89%) |
|
| |||
| Chloroma Sites | Spine 5 Extremity 7 Pelvis 2 GU§ 4 Abdomen 5 H/N‖ 14 Chest wall/Mediastinum 3 |
Spine 4 Extremity 3 Pelvis 1 GU 1 Abdomen 1 H/N 14 |
Spine 1 Extremity 4 Pelvis 1 GU 3 Abdomen 4 Chest wall/Mediastinum 3 |
|
| |||
| Complete Response to Treatment | 35 (92%) | 22 (97%) | 13 (81%) |
|
| |||
| Patients Developing a Second Chloroma | 8 (21%) | 4 (18%) | 4 (25%) |
|
| |||
| Median Survival Since Chloroma Diagnosis (months) | 23 (1-179) | 15 (1-108) | 61 (7-179) |
Abbreviations:
*
= acute myeloid leukemia;
†
= chronic myeloid leukemia;
††
= myleodysplastic syndrome;
§
= genitourinary;
‖
= head and neck.